CTL-Mediated Elimination of Replication Competent vs. Defective HIV Proviruses from Natural Latent Reservoirs: Roles of Antigen Specificity and Functional Characteristics
CTL介导从天然潜伏病毒库中消除复制能力与缺陷型HIV原病毒:抗原特异性和功能特征的作用
基本信息
- 批准号:9411495
- 负责人:
- 金额:$ 39.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-03 至 2018-06-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemAddressAdherenceAlpha CellAnatomyAnti-Retroviral AgentsAntigen TargetingAntigensAutologousAutomobile DrivingAvidityBiological AssayCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCD8B1 geneCell LineCellsCharacteristicsClinicalClinical TrialsClone CellsConsensusCytotoxic T-LymphocytesDNADataDevelopmentDimensionsEffectivenessEpitopesFutureGranzymeHIVHIV InfectionsHIV SeropositivityHealthHealth Services AccessibilityImmuneImmune systemImmunologicsIn VitroIndividualInfectionInterventionLatent VirusLymphoid FollicleMeasurementMediatingModelingModernizationMosaicismMutationOutcomeParticipantPatientsPeptide LibraryPeptidesPharmaceutical PreparationsPhenotypePlayPopulationProcessProteinsProteomeProvirusesRegimenResearch DesignRoleSamplingSeedsShockSpecificityT-LymphocyteTestingViralViral reservoirViremiaVirusVirus LatencyVirus ReplicationWorkantiretroviral therapybasecell fixationcohortcytotoxicityexhaustionexperimental studyfunctional disabilityimprovedin vivokillingspandemic diseaseperforinpurgeresponsesocialtherapy designtherapy developmenttoolviral reboundvirology
项目摘要
Although modern therapies have improved the outlooks for people living with HIV/AIDS
(PLWHA) they are unable to cure infection, leaving these individuals burdened by a
lifelong commitment to expensive antiretroviral medication. It has also become clear that
these treatments do not fully restore health, nor do they address the negative social
issues associated with being HIV positive. The development of a safe and effective HIV
cure would thus greatly improve the lives of PLWHA. A major obstacle to curing HIV
infection is the establishment of reservoirs of hidden or ‘latent’ virus which evade the
immune system and can re-seed infection if an individual stops antiretroviral therapy.
Efforts are underway to attempt to purge these HIV reservoirs. There is theoretically
achievable by combining ‘latency reversing agents’ (LRAs) capable of exposing hidden
virus with immune effectors such as killer T-cells that can then eliminate these cells, the
so-called ‘shock and kill’ approach. The viability of the shock and kill strategy is
supported by in vitro experiments using cell line models of latency, where combinations
of LRAs with killer T-cells can reduce HIV reservoirs. However, clinical trials that have
attempted to achieve this in vivo have yielded disappointing results. In preliminary
studies, we have attempted to bridge this gap by determining if combinations of LRAs
with killer T-cells could eliminate HIV from patient CD4+ T-cell samples in vitro. We made
the surprising observation that this consistently resulted in the elimination of the
defective HIV proviruses that make up the majority of HIV DNA, without impacting the
intact inducible proviruses that need to be eliminated to cure infection. In the current
project we propose the testing of different combinations of HIV-specific killer T-cells and
LRAs in this assay, in the hopes of identifying combinations that are able to more
effectively target intact inducible proviruses. Our study design will allow us to identify
general features of both killer T-cells and of LRAs that are associated with effective
elimination of intact inducible proviruses. In the process of perturbing these natural HIV
reservoirs, we will also test a wide range of reservoir measurement assays to determine
which best reflect depletions in intact inducible proviruses versus of total/defective
proviruses. Our study will thus provide critical guidance both for the design of
interventions aimed at curing HIV infection in future clinical trials, and for the selection
and interpretation of reservoir measurement assays to be used in these studies.
尽管现代疗法改善了艾滋病毒/艾滋病患者的前景
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
R. Brad Jones其他文献
R. Brad Jones的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('R. Brad Jones', 18)}}的其他基金
Enhancing Susceptibility of HIV Reservoirs to CTL Through a Discovery to Translational Approach
通过从发现到转化的方法增强 HIV 病毒库对 CTL 的易感性
- 批准号:
10676387 - 财政年份:2023
- 资助金额:
$ 39.88万 - 项目类别:
A participant-derived xenograft mouse model to study T-cell-mediated viral control and mRNA vaccine strategies
参与者衍生的异种移植小鼠模型,用于研究 T 细胞介导的病毒控制和 mRNA 疫苗策略
- 批准号:
10483703 - 财政年份:2022
- 资助金额:
$ 39.88万 - 项目类别:
Mechanisms of CTL Resistance in HIV Reservoirs
HIV病毒库中CTL耐药机制
- 批准号:
10548335 - 财政年份:2022
- 资助金额:
$ 39.88万 - 项目类别:
A participant-derived xenograft mouse model to study T-cell-mediated viral control and mRNA vaccine strategies
参与者衍生的异种移植小鼠模型,用于研究 T 细胞介导的病毒控制和 mRNA 疫苗策略
- 批准号:
10683221 - 财政年份:2022
- 资助金额:
$ 39.88万 - 项目类别:
Mechanisms of CTL Resistance in HIV Reservoirs
HIV病毒库中CTL耐药机制
- 批准号:
10669775 - 财政年份:2022
- 资助金额:
$ 39.88万 - 项目类别:
Characterization of a Memory CD4+ T-cell Humanized Mouse Model for the Evaluation of Autologous Cell Therapies and Studies of HIV Persistence
用于评估自体细胞疗法和 HIV 持久性研究的记忆 CD4 T 细胞人源化小鼠模型的表征
- 批准号:
10242093 - 财政年份:2020
- 资助金额:
$ 39.88万 - 项目类别:
Characterization of a Memory CD4+ T-cell Humanized Mouse Model for the Evaluation of Autologous Cell Therapies and Studies of HIV Persistence
用于评估自体细胞疗法和 HIV 持久性研究的记忆 CD4 T 细胞人源化小鼠模型的表征
- 批准号:
10013679 - 财政年份:2020
- 资助金额:
$ 39.88万 - 项目类别:
CTL-Mediated Elimination of Replication Competent vs. Defective HIV Proviruses from Natural Latent Reservoirs: Roles of Antigen Specificity and Functional Characteristics
CTL介导从天然潜伏病毒库中消除复制能力与缺陷型HIV原病毒:抗原特异性和功能特征的作用
- 批准号:
9766182 - 财政年份:2018
- 资助金额:
$ 39.88万 - 项目类别:
BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication
相信:从床到床增强淋巴细胞输注可实现病毒根除
- 批准号:
9976444 - 财政年份:2018
- 资助金额:
$ 39.88万 - 项目类别:
CTL-Mediated Elimination of Replication Competent vs. Defective HIV Proviruses from Natural Latent Reservoirs: Roles of Antigen Specificity and Functional Characteristics
CTL介导从天然潜伏病毒库中消除复制能力与缺陷型HIV原病毒:抗原特异性和功能特征的作用
- 批准号:
10219055 - 财政年份:2018
- 资助金额:
$ 39.88万 - 项目类别:
相似海外基金
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 39.88万 - 项目类别:
Evaluating Centralizing Interventions to Address Low Adherence to Lung Cancer Screening Follow-up in Decentralized Settings
评估集中干预措施,以解决分散环境中肺癌筛查随访依从性低的问题
- 批准号:
10738120 - 财政年份:2023
- 资助金额:
$ 39.88万 - 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
- 批准号:
10526768 - 财政年份:2022
- 资助金额:
$ 39.88万 - 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
- 批准号:
10701072 - 财政年份:2022
- 资助金额:
$ 39.88万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10679092 - 财政年份:2021
- 资助金额:
$ 39.88万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10432133 - 财政年份:2021
- 资助金额:
$ 39.88万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10327065 - 财政年份:2021
- 资助金额:
$ 39.88万 - 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
- 批准号:
10377366 - 财政年份:2019
- 资助金额:
$ 39.88万 - 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
- 批准号:
10574496 - 财政年份:2019
- 资助金额:
$ 39.88万 - 项目类别:
Targeted interventions to address the multi-level effects of gender-based violence on PrEP uptake and adherence among adolescent girls and young women in Kenya
有针对性的干预措施,以解决性别暴力对肯尼亚少女和年轻妇女接受和坚持 PrEP 的多层面影响
- 批准号:
9403567 - 财政年份:2017
- 资助金额:
$ 39.88万 - 项目类别: